Matinas BioPharma Holdings Inc（MTNB）の財務MTNBMatinas BioPharma Holdings Inc

Evaluating the bottom line, Matinas BioPharma Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -154.28%, provide a clear picture of how effectively MTNB converts its operational activities into shareholder value.

In the context of the broader market, MTNB competes directly with industry leaders such as KPTI and ARTL. With a market capitalization of $1.21M, it holds a leading position in the sector. When comparing efficiency, MTNB's gross margin of N/A stands against KPTI's 96.75% and ARTL's N/A. Such benchmarking helps identify whether Matinas BioPharma Holdings Inc is trading at a premium or discount relative to its financial performance.

Matinas BioPharma has shown continuous losses, with net income to common reaching -$8.43 million in Q4 2024 and -$1.32 million in Q2 2026. The gross profit has been negative in multiple quarters, indicating ongoing financial struggles.